Angiotensin II type 2 receptor agonist treatment of doxorubicin induced heart failure

References

• Abbasloo E, Najafipour H, Vakili A. 2020. Chronic treatment with apelin, losartan and their combination reduces myocardial infarct size and improves cardiac mechanical function. Clin Exp Pharmacol Physiol. 47:393–402. doi:10.1111/1440-1681.13195.
   PubMed Web of Science ®Google Scholar
• Arslan AK, Yasar S, Colak C, Yologlu S. 2018. WSSPAS: an interactive web application for sample size and power analysis with R using Shiny. Turk Klin J Biostat. 10:224–246. doi:10.5336/biostatic.2018-62787.
   Google Scholar
• Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG. 2001. Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. Am J Physiol Heart Circ Physiol. 281:2337–2365. doi:10.1152/ajpheart.2001.281.6.H2337.
   Web of Science ®Google Scholar
• Blankley CJ, Hodges JC, Klutchko SR, Himmelsbach RJ, Chucholowski A, Connolly CJ, Neergaard SJ, Van Nieuwenhze MS, Sebastian A, Quin J III. 1991. Synthesis and structure-activity relationships of a novel series of nonpeptide angiotensin II receptor binding inhibitors specific for the AT2 subtype. J Med Chem. 34:3248–3260. doi:10.1021/jm00115a014.
   PubMed Web of Science ®Google Scholar
• Booz GW, Baker KM. 1996. Role of type 1 and type 2 angiotensin receptors in angiotensin II–Induced cardiomyocyte hypertrophy. Hypertension. 28:635–640. doi:10.1161/01.HYP.28.4.635.
   PubMed Web of Science ®Google Scholar
• Bosnyak S, Welungoda IK, Hallberg A, Alterman M, Widdop RE, Jones ES. 2010. Stimulation of angiotensin AT2 receptors by the non-peptide agonist, compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol. 159:709–716. doi:10.1111/j.1476-5381.2009.00575.x.
   PubMed Web of Science ®Google Scholar
• Carey RM, Jin XH, Siragy HM. 2001. Role of the angiotensin AT2 receptor in blood pressure regulation and therapeutic implications. Am J Hypertens. 14:98–102. doi:10.1016/S0895-7061(01)02076-3.
   PubMed Web of Science ®Google Scholar
• Chow BSM, Allen TJ. 2016. Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease. Clin Sci. 130:1307–1326. doi:10.1042/CS20160243.
   PubMed Web of Science ®Google Scholar
• Cigremis Y, Parlakpinar H, Polat A, Colak C, Ozturk F, Sahna E, Ermis N, Acet A. 2006. Beneficial role of aminoguanidine on acute cardiomyopathy related to doxorubicin-treatment. Mol Cell Biochem. 285:149–154. doi:10.1007/s11010-005-9072-8.
   PubMed Web of Science ®Google Scholar
• De Mello WC, Danser AH. 2000. Angiotensin II and the heart on the intracrine renin angiotensin system. Hypertension. 35:1183–1188. doi:10.1161/01.HYP.35.6.1183.
   PubMed Web of Science ®Google Scholar
• Disli OM, Sarihan E, Colak MC, Vardi N, Polat A, Yagmur J, Tamtekin B, Parlakpinar H. 2013. Effects of molsidomine against doxorubicin-induced cardiotoxicity in rats. Eur Surg Res. 51:79–90. doi:10.1159/000354807.
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Horiuchi M. 1996. Differential expression of angiotensin receptor subtypes in the myocardium: a hypothesis. Eur Heart J. 17:978–980. doi:10.1093/oxfordjournals.eurheartj.a015016.
   PubMed Web of Science ®Google Scholar
• Fatima N, Patel SN, Hussain T. 2021. Angiotensin II type 2 receptor: a target for protection against hypertension, metabolic dysfunction, and organ remodeling. Hypertension. 77:1845–1856. doi:10.1161/HYPERTENSIONAHA.120.11941.
   PubMed Web of Science ®Google Scholar
• Gohlke P, Pees C, Unger T. 1998. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension. 31:349–355. doi:10.1161/01.HYP.31.1.349.
   PubMed Web of Science ®Google Scholar
• Guo R, Hua Y, Ren J, Bornfeldt KE, Nair S. 2019. Correction: cardiomyocyte-specific disruption of cathepsin K protects against doxorubicin-induced cardiotoxicity. Cell Death Dis. 10:933. doi:10.1038/s41419-019-2113-0.
   PubMed Web of Science ®Google Scholar
• Horiuchi M, Akishita M, Dzau VJ. 1999. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Brief Rev. 33:613–621. doi:10.1161/01.HYP.33.2.613.
   Google Scholar
• Kaldir H.M., Tatli E, Turgut B, Vural O. 2002. Doxorubicin Induced Cardiotoxicity. Clin J Cardiol. 15:416–421
   Google Scholar
• Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F, Sommerfeld M, Kemnitz UR, Curato C, Namsolleck P, Tschope C, Hallberg A, Alterman M, Hucko T, Paetsch I, Dietrich T, Schnackenburg B, Graf K, Dahlof B, Kintscher U, Unger T, Steckelings UM. 2008. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation. 118:2523–2532. doi:10.1161/CIRCULATIONAHA.108.784868.
   PubMed Web of Science ®Google Scholar
• Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA. 2009. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomized, double-blind trial. Lancet. 374:1840–1848. doi:10.1016/S0140-6736(09)61913-9.
   PubMed Web of Science ®Google Scholar
• Koulis C, Chow BS, McKelvey M, Steckelings UM, Unger T, Thallas-Bonke V, Thomas MC, Cooper ME, Jandeleit-Dahm KA, Allen TJ. 2015. AT2R agonist, compound 21, is renoprotective against type 1 diabetic nephropathy. Hypertension. 65:1073–1081. doi:10.1161/HYPERTENSIONAHA.115.05204.
   PubMed Web of Science ®Google Scholar
• Lauer D, Slavic S, Sommerfeld M, Thöne-Reineke C, Sharkovska Y, Hallberg A, Dahlöf B, Kintscher U, Unger T, Steckelings UM, Kaschina E. 2014. Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/matrix metalloproteinase 9 axis and transforming growth factor β1 in the rat heart. Hypertension. 63:60–67. doi:10.1161/HYPERTENSIONAHA.113.02522.
   PubMed Web of Science ®Google Scholar
• Lopez JJ, Lorell BH, Ingelfinger JR, Weinberg EO, Schunkert H, Diamant D, Tang SS. 1994. Distribution and function of cardiac angiotensin AT1-and AT2-receptor subtypes in hypertrophied rat hearts. Am J Physiol. 36:844–852. doi:10.1152/ajpheart.1994.267.2.H844.
   Google Scholar
• Matouk AI, Taye A, Heeba GH, El-Moselhy MA. 2013. Quercetin augments the protective effect of losartan against chronic doxorubicin cardiotoxicity in rats. Env Toxicol Pharmacol. 36:443–450. doi:10.1016/j.etap.2013.05.006.
   PubMed Web of Science ®Google Scholar
• Najafi M, Hooshangi Shayesteh MR, Mortezaee K, Farhood B, Haghi-Aminjan H. 2019. The role of melatonin on doxorubicin-induced cardiotoxicity: a systematic review. Life Sci. 241:117–173. doi:10.1016/j.lfs.2019.117173.
   Web of Science ®Google Scholar
• Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. 1995. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest. 95:46–54. doi:10.1172/JCI117675.
   PubMed Web of Science ®Google Scholar
• Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K, Maruyama K, Masaki H, Tsutumi Y, Shibazaki Y, Iwasaka T, Inada M. 1997. Angiotensin type 2 receptors are re-expressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation. 96:3954–3962. doi:10.1161/01.CIR.96.11.3954.
   PubMed Web of Science ®Google Scholar
• Ozhan O, Parlakpinar H, Acet A. 2020. Comparison of the effects of losartan, captopril, angiotensin II type 2 receptor agonist compound 21, and MAS receptor agonist AVE 0991 on myocardial ischemia–reperfusion necrosis in rats. Fund Clin Pharmacol. 35:669–680. doi:10.1111/fcp.12599.
   PubMedGoogle Scholar
• Parlakpinar H, Ozer MK, Acet A. 2011. Effects of captopril and angiotensin II receptor blockers (AT1, AT2) on myocardial ischemia–reperfusion induced infarct size. Cytokine. 56:688–694. doi:10.1016/j.cyto.2011.09.002.
   PubMed Web of Science ®Google Scholar
• Rogg H, de Gasparo M, Graedel E, Stulz P, Burkart F, Eberhard M, Erne P. 1996. Angiotensin II receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction. Eur Heart J. 17:1112–1120. doi:10.1093/oxfordjournals.eurheartj.a015008.
   PubMed Web of Science ®Google Scholar
• Sahna E, Parlakpinar H, Ozer MK, Ozturk F, Ozugurlu F, Acet A. 2003. Melatonin protects against myocardial doxorubicin toxicity in rats: role of physiological concentrations. J Pineal Res. 35:257–261. doi:10.1034/j.1600-079X.2003.00084.x.
   PubMed Web of Science ®Google Scholar
• Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, Drexler H. 1994. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation. 89:2273–2282. doi:10.1161/01.CIR.89.5.2273.
   PubMed Web of Science ®Google Scholar
• Shi Y, Moon M, Dawood S, McManus B, Liu PP. 2011. Mechanisms and management of doxorubicin cardiotoxicity. Herz. 36:296–305. doi:10.1007/s00059-011-3470-3.
   PubMed Web of Science ®Google Scholar
• Suvarne SK, Layton C, Bancroft JD. 2012. Bancroft’s theory and practice of histological technique. 7th ed. Churchill Livingstone, Elsevier, London.
   Google Scholar
• Toko H, Oka T, Zou Y, Sakamoto M, Mizukami M, Sano M, Yamamoto R, Sugaya T, Komuro I. 2002. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res. 25:597–603. doi:10.1291/hypres.25.597.
   PubMed Web of Science ®Google Scholar
• Ulutas Z, Ermis N, Ozhan O, Parlakpinar H, Vardi N, Ates B, Colak C. 2020. The protective effects of compound 21 and valsartan in isoproterenol-induced myocardial injury in rats. Cardiovasc Toxicol. 21:17–28. doi:10.1007/s12012-020-09590-6.
   PubMed Web of Science ®Google Scholar
• Unger T. 1999. The angiotensin type 2 receptor: variations on an enigmatic theme. J Hypertens. 17:1775–1786. doi:10.1097/00004872-199917121-00001.
   PubMed Web of Science ®Google Scholar
• Verdonk K, Durik M, Abd-Alla N, Batenburg WW, van den Bogaerdt AJ, van Veghel R, Roks AJ, Danser AH, van Esch JH. 2012. Compound 21 induces vasorelaxation via an endothelium- and angiotensin II type 2 receptor-independent mechanism. Hypertension. 60:722–729. doi:10.1161/HYPERTENSIONAHA.112.196022.
   PubMed Web of Science ®Google Scholar
• Wan Y, Wallinder C, Johansson B, Holm M, Mahalingam AK, Wu X, Botros M, Karlén A, Pettersson A, Nyberg F, Fändriks L, Hallberg A, Alterman M. 2004. First reported non-peptide AT1 receptor agonist (L-162,313) acts as an AT2 receptor agonist in vivo. J Med Chem. 47:1536–1546. doi:10.1021/jm031031i.
   PubMed Web of Science ®Google Scholar
• Wharton J, Morgan K, Rutherford RA. 1998. Differential distribution of angiotensin AT2 receptors in the normal and failing human heart. J Pharmacol Exp Ther. 284:323–336.
   PubMed Web of Science ®Google Scholar
• Xiao L, Hu SQ, Wang LY, Liu JX, Li XY. 2015. Losartan improves the distribution and efficacy of doxorubicin in CT26 tumor. Eur Rev Med Pharmacol Sci. 19:3763–3769.
   PubMed Web of Science ®Google Scholar
• Yamada T, Akishita M, Pollman MJ, Gibbons GH, Dzau VJ, Horiuchi M. 1998. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin type I receptor action: an in vitro gene transfer study. Life Sci. 63:289–295. doi:10.1016/S0024-3205(98)00448-2.
   Web of Science ®Google Scholar
• Yu X, Ruan Y, Huang X, Dou L, Lan M, Cui J, Chen B, Gong H, Wang Q, Yan M, Sun S, Qiu Q, Zhang X, Man Y, Tang W, Li J, Shen T. 2020. Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes. Biochem Biophys Res Commun. 523:140–146. doi:10.1016/j.bbrc.2019.12.027.
   PubMed Web of Science ®Google Scholar
• Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM. 2017. Authors/Task force members; ESC Committee for Practice Guidelines (CPG); document reviewers. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail. 19:9–42. doi:10.1002/ejhf.654.
   PubMed Web of Science ®Google Scholar
• Zhai J, Tao L, Zhang S, Gao H, Zhang Y, Sun J, Song Y, Qu X. 2020. Calycosin ameliorates doxorubicin-induced cardiotoxicity by suppressing oxidative stress and inflammation via the sirtuin 1–NOD-like receptor protein 3 pathway. Phytother Res. 34:649–659. doi:10.1002/ptr.6557.
   PubMed Web of Science ®Google Scholar
• Zong WN, Yang XH, Chen XM, Huang HJ, Zheng HJ, Qin XY, Yong YH, Cao K, Huang J, Lu XZ. 2011. Regulation of angiotensin-(1–7) and angiotensin II type 1 receptor by telmisartan and losartan in adriamycin-induced rat heart failure. Acta Pharmacol Sin. 32:1345–1350. doi:10.1038/aps.2011.96.
   PubMed Web of Science ®Google Scholar